Navigation Links
China Sky One Medical Announces First Quarter 2010 Results
Date:5/18/2010

HARBIN, China, May 18 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

    First Quarter 2010 Financial Highlights
    -- Total revenues increased 16.4% year-over-year to $28.9 million
    -- Gross profit rose 15.1% to $21.6 million
    -- Operating income grew 11.8% to $10.1 million
    -- GAAP net income, including a non-cash gain from change in the fair
       value of derivative warrant liability, increased 73.8% year-over-year
       to $12.6 million, or $0.74 per diluted share
    -- Excluding the non-cash gain, non-GAAP adjusted net income rose 5.8% to
       $7.7 million or $0.45 per diluted share

    First Quarter 2010 Accomplishments
    -- Received CE certification for Myocardial Infarction and Urine
       Microalbumin Diagnostic Kits.
    -- Commenced commercial launch of Oxymetazoline Hydrochloride Nasal Drops
       and Moschus Liniment for Pain Relief in March 2010.
    -- Myocardial Infarction Diagnostic Kit and Antroquinonol (Hocena) capsule
       were recognized as "National Innovation Project" and "Breakthrough
       Drug" by Chinese government, respectively.
    -- Shifted R&D focus of Heilongjiang Tianlong Pharmaceutical Company, the
       Company's wholly owned subsidiary, from external use medicines to
       antibiotics and cardiac drugs.
    -- Listed the Company's common shares on the NASDAQ Global Select Market
       o
'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... , ... September 01, 2015 , ... ... is now offering the MonaLisa Touch® , an innovative vaginal health laser ... Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that causes ...
(Date:9/1/2015)... Florida (PRWEB) , ... September ... ... of Professional Background Screeners (NAPBS®) has announced that Edge Information Management ... conducted by the Background Screening Credentialing Council (BSCC). , “Achieving and ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and government entities, announced today that it has hired Scott Sanderson, an experienced ... In this capacity, Sanderson will be responsible for establishing and managing new client ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a ... followed men and women for 19 years and found that, among those who had ... multivitamins. , The report is part of the September 2015 issue of “Natural Insights ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... ease the pain during labor. But such epidurals proved to ... Safety Agency (NPSA) in response has issued warnings to doctors ... 200 errors have been committed due a period of one ... at the base of the spine, but in some cases ...
Microsoft founder Bill Gates has said that his decision to devote more time to philanthropy was a...
... of partially hydrogenated oil laden with trans fats has targeted ... in the Public Interest filed the suit with the Superior ... either stop using partially hydrogenated oil or use signs to ... 50,000 Americans usually succumb to death annually because of using ...
... a united effort from the Western Australian Government and BHP ... health services //in the Pilbara, spread over a six year ... a post-natal depression support service in Newman. The Port Hedland ... ,While confirming that the construction of the hospital will ...
... tried to analyze the many reasons why some teen girls ... IVF treatments //. In his reading, they are just going ... ridiculed. ,Laurence Shaw, the deputy medical director of ... opinion that, it is the internal program charted by nature ...
... being exposed to too much light at night disrupts ... tumours //. Women particularly those who work night shifts ... particularly risk. ,For the first time now ... Institute of Environmental Health Sciences, have demonstrated that long ...
Cached Medicine News:Health News:Exposure To Artificial Light Could Be Cancerous 2
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: